Thursday, October 15, 2026
ExploreSearch
Finance Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· June 1, 2026

No Rate Cuts Until 2027? Grab These High-Yielding Safe Dividend Kings Now

View original at finance.yahoo.com
No Rate Cuts Until 2027? Grab These High-Yielding Safe Dividend Kings Now Persistent inflation is likely to keep the Federal Reserve from cutting rates until well into 2027…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Five screened Dividend Kings are rated Buy by top Wall Street firms and are outstanding ideas for growth and income investors

    60% confidence

  • Bank of America economists do not expect Fed rate cuts until mid- or late 2027

    60% confidence

  • Even with a peace agreement with Iran, oil will remain above the $50–$60 per barrel level that was forecast for 2026, combined with rising food prices, potentially forcing the Fed to hold rates for another year or longer

    60% confidence

  • Wall Street firms increasingly believe the Federal Reserve cannot lower rates until 2027

    60% confidence

  • Rising costs in services, housing, energy, and tariffs are keeping inflation above the Fed's 2% target while a strong labor market supports wage pressures

    60% confidence

  • 36 of the 58 Dividend Kings members are outperforming the broader market year to date in 2026

    60% confidence

  • Dividend Kings tend to underperform in bull markets but outperform relative to the market during more volatile or bearish stretches

    60% confidence

Data points we hold from this source

Federal Reserve · parameter count2 percent
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com
No Rate Cuts Until 2027? Grab These High-Yielding Safe Dividend Kings Now — Source | Via News | Finance Via News